On Thursday 6th February, we attended the Medlink South West Healthcare Innovation awards, where we were absolutely delighted to be awarded best new start up. Chaired by Professor Richard Luxton, and with [...]
Neuronostics is delighted to be nominated in the 'Start up' category for the Medilink South West awards to be held in Bristol on Thursday February 6th. The event itself offers an invaluable [...]
Professor John Terry (co-founder of Neuronostics and Professor at the University of Birmingham) has been invited to deliver a presentation at this year’s International League Against Epilepsy (ILAE) British Branch Annual Scientific [...]
18th December 2019 Neuronostics are excited to announce plans to establish a user-group to help shape its products and offerings. We are delighted to announce the first member of the group is Simon [...]
Wessel Woldman (our Scientific Director) delivered the opening lecture at the Birmingham Epilepsy Research Network meeting on Monday November 25th. The annual event, now in its 10th year, brings together clinicians, neurophysiologists, [...]
Neuronostics Ltd, today announces that it has been selected by Microsoft for a new programme designed to help startups get off the ground. Microsoft for Startups will provide up to $500 million worth of [...]
Neuronostics, the developer of #BioEP, the revolutionary epilepsy assessment tool, announces the appointment of Dr. Wessel (Wes) Woldman as Scientific Director. Dr. Woldman, will lead and manage application research and development of [...]
Neuronostics Ltd, developer of the revolutionary seizure susceptibility assessment technology called #BioEP, announces the appointment of Ross Parkman as Technical & Operations Director. Mr Parkman, who previously 15 years at IT solutions [...]
Neuronostics Ltd, announces that in conjunction with the University of Exeter, it has been awarded £504,000 grant funding to accelerate the development of its potentially revolutionary seizure susceptibility technology called #BioEP. The [...]